Title
Phase II doseselection, randomized double-blind trial of the ASI, BI 690517, alone and in combination with EMPA in people with CKD
Document Type
Presentation
Publication Date
6-2023
Publication Title
60th ERA Congress 2023
Keywords
washington; spokane; pmrc
Abstract
This study is investigating the efficacy and safety of three doses of BI 690517, alone and in combination with empagliflozin (EMPA), on top of an ACEi or ARB, for treatment of CKD with or without type 2 diabetes. This study will provide key data on the potential synergistic kidney-protective effects and safety of combination therapy with BI 690517 plus EMPA, as well as data on monotherapy, for CKD with or without type 2 diabetes. Findings will inform BI 690517 dose selection for further clinical trial development.
Clinical Institute
Kidney & Diabetes
Department
Nephrology
Department
Endocrinology
Recommended Citation
Rossing, P; Tuttle, Katherine; and Full List of Authors in Comments, "Phase II doseselection, randomized double-blind trial of the ASI, BI 690517, alone and in combination with EMPA in people with CKD" (2023). Articles, Abstracts, and Reports. 7294.
https://digitalcommons.providence.org/publications/7294
Comments